This activity is supported by an unrestricted educational grant from Bristol-Myers Squibb, Lilly USA, LLC, and Merck & Co.
Collaborative Management of Patients with Gastric Cancer
David H. Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center
Steve Malangone, MSN, FNP-C, AOCNP®
University of Arizona Cancer Center
Advanced gastric and esophageal cancers are associated with poor outcomes. However, as knowledge of disease biology improves, treatment options are increasing. Genomic profiling has identified targetable mutations or biomarkers, such as HER2. Immunotherapies such as checkpoint inhibitors may be approved for gastrointestinal malignancies in the very near future. This program provides an overview of clinical trials, new treatment options, as well as practical clinical information regarding diagnosis, staging, monitoring, and managing side effects to treatment, in order to ameliorate clinical confidence and patient outcomes.
These CE/CME/CEU accredited activities are jointly provided by